Forte Biosciences (FBRX) Other Non Operating Income (2018 - 2026)
Forte Biosciences (FBRX) reported Other Non Operating Income of $676000.0 for Q1 2026, up 44.44% year-over-year from $468000.0 in Q1 2025, and up 135.67% quarter-over-quarter from -$1.9 million in Q4 2025.
Forte Biosciences (FBRX) Other Non Operating Income (2018 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has 9 years of Other Non Operating Income data on file, last reported at $676000.0 in Q1 2026.
- Other Non Operating Income for Q1 2026 came in at $676000.0, up 44.44% year-over-year; the trailing twelve-month figure through Mar 2026 was -$188000.0 (down 77.36% YoY), and the FY2025 annual result was -$396000.0, down 108.42% from the prior year.
- Other Non Operating Income climbed to $676000.0 in Q1 2026 per FBRX's latest filing, from -$1.9 million in the prior quarter.
- Over five years, Other Non Operating Income peaked at $701000.0 in Q3 2025 and troughed at -$1.9 million in Q4 2025.
- A 5-year average of -$9941.2 and a median of $138000.0 in 2023 frame the typical range for Other Non Operating Income.
- On a YoY basis, Other Non Operating Income climbed as much as 1034.78% in 2023 and fell as far as 515.0% in 2023.
- A 5-year view of Other Non Operating Income shows it stood at -$100000.0 in 2022, then tumbled by 515.0% to -$615000.0 in 2023, then slumped by 81.79% to -$1.1 million in 2024, then plunged by 69.5% to -$1.9 million in 2025, then jumped by 135.67% to $676000.0 in 2026.
- Business Quant data shows FBRX's Other Non Operating Income at $676000.0 in Q1 2026, -$1.9 million in Q4 2025, and $701000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Forte Biosciences | 70.77 Mn | 12.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 676,000.00 |
| Dec 31, 2025 | -1.90 Mn |
| Sep 30, 2025 | 701,000.00 |
| Jun 30, 2025 | 330,000.00 |
| Mar 31, 2025 | 468,000.00 |
| Dec 31, 2024 | -1.12 Mn |
| Sep 30, 2024 | 237,000.00 |
| Jun 30, 2024 | 307,000.00 |
| Mar 31, 2024 | 384,000.00 |
| Dec 31, 2023 | -615,000.00 |
| Sep 30, 2023 | 261,000.00 |
| Jun 30, 2023 | 138,000.00 |
| Mar 31, 2023 | 102,000.00 |
| Dec 31, 2022 | -100,000.00 |
| Sep 30, 2022 | 23,000.00 |
| Jun 30, 2022 | -15,000.00 |
| Mar 31, 2022 | -53,000.00 |
| Dec 31, 2021 | -42,000.00 |
| Sep 30, 2021 | -52,000.00 |
| Jun 30, 2021 | -65,000.00 |